Pursuant to clause 33 of the Listing Obligations and Disclosure requirements (LODR), Regulations, 2015, Glaxosmithkline Pharmaceuticals has informed that a meeting of the Board of Directors of the Company will be held on Friday, 2nd February, 2018, to consider and approve Un-Audited Financial Results for the third quarter and nine months ended 31st December, 2017.
The above information is a part of company’s filings submitted to BSE.